Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice

Tao Ma, Xueliang Du, Joseph E. Pick, Guangzhi Sui, Michael Brownlee, Eric Klann

Research output: Contribution to journalArticle

Abstract

Glucagon-like peptide-1 (GLP-1) is an endogenous intestinal peptide that enhances glucose-stimulated insulin secretion. Its natural cleavage product GLP-1(9-36)amide possesses distinct properties and does not affect insulin secretion. Here we report that pretreatment of hippocampal slices with GLP-1(9-36)amide prevented impaired long-term potentiation (LTP) and enhanced long-term depression induced by exogenous amyloid β peptide Aβ(1-42). Similarly, hippocampal LTP impairments in amyloid precursor protein/presenilin 1 (APP/PS1) mutant mice that model Alzheimer's disease (AD) were prevented by GLP-1(9-36)amide. In addition, treatment of APP/PS1 mice with GLP-1(9-36)amide at an age at which they display impaired spatial and contextual fear memory resulted in a reversal of their memory defects. At the molecular level, GLP-1(9-36)amide reduced elevated levels of mitochondrial-derived reactive oxygen species and restored dysregulated Aktglycogen synthase kinase-3β signaling in the hippocampus of APP/PS1 mice. Our findings suggest that GLP-1(9-36)amide treatment may have therapeutic potential for AD and other diseases associated with cognitive dysfunction.

Original languageEnglish (US)
Pages (from-to)13701-13708
Number of pages8
JournalJournal of Neuroscience
Volume32
Issue number40
DOIs
StatePublished - Oct 3 2012

Fingerprint

Neuronal Plasticity
Glucagon-Like Peptide 1
Memory Disorders
Alzheimer Disease
Amyloid beta-Protein Precursor
Long-Term Potentiation
Insulin
Amyloid
Fear
glucagon-like peptide-1 (9-36)-amide
Reactive Oxygen Species
Hippocampus
Phosphotransferases
Depression
Glucose
Peptides
mouse presenilin 1

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice. / Ma, Tao; Du, Xueliang; Pick, Joseph E.; Sui, Guangzhi; Brownlee, Michael; Klann, Eric.

In: Journal of Neuroscience, Vol. 32, No. 40, 03.10.2012, p. 13701-13708.

Research output: Contribution to journalArticle

Ma, Tao ; Du, Xueliang ; Pick, Joseph E. ; Sui, Guangzhi ; Brownlee, Michael ; Klann, Eric. / Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice. In: Journal of Neuroscience. 2012 ; Vol. 32, No. 40. pp. 13701-13708.
@article{f38661a7ca504a74b036a34bd99128fd,
title = "Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice",
abstract = "Glucagon-like peptide-1 (GLP-1) is an endogenous intestinal peptide that enhances glucose-stimulated insulin secretion. Its natural cleavage product GLP-1(9-36)amide possesses distinct properties and does not affect insulin secretion. Here we report that pretreatment of hippocampal slices with GLP-1(9-36)amide prevented impaired long-term potentiation (LTP) and enhanced long-term depression induced by exogenous amyloid β peptide Aβ(1-42). Similarly, hippocampal LTP impairments in amyloid precursor protein/presenilin 1 (APP/PS1) mutant mice that model Alzheimer's disease (AD) were prevented by GLP-1(9-36)amide. In addition, treatment of APP/PS1 mice with GLP-1(9-36)amide at an age at which they display impaired spatial and contextual fear memory resulted in a reversal of their memory defects. At the molecular level, GLP-1(9-36)amide reduced elevated levels of mitochondrial-derived reactive oxygen species and restored dysregulated Aktglycogen synthase kinase-3β signaling in the hippocampus of APP/PS1 mice. Our findings suggest that GLP-1(9-36)amide treatment may have therapeutic potential for AD and other diseases associated with cognitive dysfunction.",
author = "Tao Ma and Xueliang Du and Pick, {Joseph E.} and Guangzhi Sui and Michael Brownlee and Eric Klann",
year = "2012",
month = "10",
day = "3",
doi = "10.1523/JNEUROSCI.2107-12.2012",
language = "English (US)",
volume = "32",
pages = "13701--13708",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "40",

}

TY - JOUR

T1 - Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice

AU - Ma, Tao

AU - Du, Xueliang

AU - Pick, Joseph E.

AU - Sui, Guangzhi

AU - Brownlee, Michael

AU - Klann, Eric

PY - 2012/10/3

Y1 - 2012/10/3

N2 - Glucagon-like peptide-1 (GLP-1) is an endogenous intestinal peptide that enhances glucose-stimulated insulin secretion. Its natural cleavage product GLP-1(9-36)amide possesses distinct properties and does not affect insulin secretion. Here we report that pretreatment of hippocampal slices with GLP-1(9-36)amide prevented impaired long-term potentiation (LTP) and enhanced long-term depression induced by exogenous amyloid β peptide Aβ(1-42). Similarly, hippocampal LTP impairments in amyloid precursor protein/presenilin 1 (APP/PS1) mutant mice that model Alzheimer's disease (AD) were prevented by GLP-1(9-36)amide. In addition, treatment of APP/PS1 mice with GLP-1(9-36)amide at an age at which they display impaired spatial and contextual fear memory resulted in a reversal of their memory defects. At the molecular level, GLP-1(9-36)amide reduced elevated levels of mitochondrial-derived reactive oxygen species and restored dysregulated Aktglycogen synthase kinase-3β signaling in the hippocampus of APP/PS1 mice. Our findings suggest that GLP-1(9-36)amide treatment may have therapeutic potential for AD and other diseases associated with cognitive dysfunction.

AB - Glucagon-like peptide-1 (GLP-1) is an endogenous intestinal peptide that enhances glucose-stimulated insulin secretion. Its natural cleavage product GLP-1(9-36)amide possesses distinct properties and does not affect insulin secretion. Here we report that pretreatment of hippocampal slices with GLP-1(9-36)amide prevented impaired long-term potentiation (LTP) and enhanced long-term depression induced by exogenous amyloid β peptide Aβ(1-42). Similarly, hippocampal LTP impairments in amyloid precursor protein/presenilin 1 (APP/PS1) mutant mice that model Alzheimer's disease (AD) were prevented by GLP-1(9-36)amide. In addition, treatment of APP/PS1 mice with GLP-1(9-36)amide at an age at which they display impaired spatial and contextual fear memory resulted in a reversal of their memory defects. At the molecular level, GLP-1(9-36)amide reduced elevated levels of mitochondrial-derived reactive oxygen species and restored dysregulated Aktglycogen synthase kinase-3β signaling in the hippocampus of APP/PS1 mice. Our findings suggest that GLP-1(9-36)amide treatment may have therapeutic potential for AD and other diseases associated with cognitive dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=84866972198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866972198&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.2107-12.2012

DO - 10.1523/JNEUROSCI.2107-12.2012

M3 - Article

C2 - 23035082

AN - SCOPUS:84866972198

VL - 32

SP - 13701

EP - 13708

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 40

ER -